Deutsche Bank
TRVI icon

Deutsche Bank’s Trevi Therapeutics TRVI Stock Holding History

Deutsche Bank’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.14M Buy
114,487
+29,732
+35% +$432K ﹤0.01% 1871
2026
Q1 		$1.01M Buy
84,755
+13,922
+20% +$156K ﹤0.01% 2175
2025
Q4 		$887K Buy
70,833
+19,193
+37% +$222K ﹤0.01% 2247
2025
Q3 		$473K Buy
51,640
+8,203
+19% +$61.5K ﹤0.01% 2571
2025
Q2 		$238K Buy
43,437
+5,811
+15% +$36.2K ﹤0.01% 2865
2025
Q1 		$237K Buy
37,626
+8,383
+29% +$40K ﹤0.01% 2877
2024
Q4 		$120K Buy
29,243
+685
+2% +$2.19K ﹤0.01% 3242
2024
Q3 		$95.4K Buy
28,558
+14,635
+105% +$43.5K ﹤0.01% 3233
2024
Q2 		$41.5K Sell
13,923
-3,894
-22% -$10.8K ﹤0.01% 3355
2024
Q1 		$61.5K Buy
+17,817
New +$39.8K ﹤0.01% 3345
2023
Q4 		– Sell
-25,070
Closed -$54.7K – 3703
2023
Q3 		$54.7K Buy
+25,070
New +$56.6K ﹤0.01% 3389

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Deutsche Bank's TRVI Position: Q2 2026 in Review

Deutsche Bank increased its Trevi Therapeutics (TRVI) stake by 35% in Q2 2026, buying an estimated $432K and bringing the position to 114,487 shares worth $2.14M. The position accounts for ﹤0.01% of the portfolio, ranked #1871.

Deutsche Bank first reported a position in TRVI in Q3 2023 and has held it in 11 quarters since. 218 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Deutsche Bank held 114,487 shares of Trevi Therapeutics worth $2.14M as of Q2 2026.
  • Deutsche Bank bought 29,732 Trevi Therapeutics shares in Q2 2026, an estimated $432K.
  • Trevi Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #1871 holding.
  • Deutsche Bank first reported a position in Trevi Therapeutics in Q3 2023 and has held it in 11 quarters since.
  • 218 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.